A Phase 1 interventional study of PF-07261271 and Placebo in Healthy, sponsored by Pfizer. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Inflammatory Bowel Diseases by Pfizer — none open to participants now, none under way, none of them phase 3. Inflammatory Bowel Diseases · Pfizer.
Among the 15 studies in Inflammatory Bowel Diseases by Pfizer, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2022, is one of 7 in phase 1, and was the 14th registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.
Browse Inflammatory Bowel Diseases studies →None of the 15 studies in Inflammatory Bowel Diseases by Pfizer is open now. The open studies under Inflammatory Bowel Diseases, anywhere →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 2 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 68 across 870 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 44 across the 11 interventional studies, 1,342 across the 2 observational. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Inflammatory Bowel Diseases by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine PF-07261271 for the potential treatment of Inflammatory Bowel Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose A
Drug: PF-07261271
Dose A
Drug: Placebo
Dose B
Drug: PF-07261271
Dose B
Drug: Placebo
Dose C
Drug: PF-07261271
Dose C
Drug: Placebo
Dose D
Drug: PF-07261271
Dose D
Drug: Placebo
Dose E
Drug: PF-07261271
Dose E
Drug: Placebo
Dose F
Drug: PF-07261271
Dose F
Drug: Placebo
Dose G
Drug: PF-07261271
Dose G
Drug: Placebo
Dose H
Drug: PF-07261271
Dose H
Drug: Placebo
IV or SC
IV or SC
Number of Participants With Treatment Emergent Adverse Events (TEAEs): SAD Cohort
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the last follow-up date, were considered as TEAEs. AEs included all SAEs and Non-SAEs.
Time frame: From start of study intervention (Day 1) up to end of study, approximately up to 15 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs): MD Cohort
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the last follow-up date, were considered as TEAEs. AEs included all SAEs and Non-SAEs.
Time frame: From start of study intervention (Day 1) up to end of study, approximately of 15.5 months
Number of Participants With Serious Adverse Events (SAEs): SAD Cohort
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAEs were defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medically significant event.
Time frame: From start of study intervention (Day 1) up to end of study, approximately up to 15 months
Number of Participants With Serious Adverse Events (SAEs): MD Cohort
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAEs were defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medically significant event.
Time frame: From start of study intervention (Day 1) up to end of study, approximately of 15.5 months
Number of Participants With Clinically Significant Changes in Vital Signs Abnormalities: SAD Cohort
Criteria for abnormal values of vital signs: systolic blood pressure (millimeters of mercury \[mmHg\]) value less than (\<) 90 mmHg, change greater than or equal to (\>=) 30 mmHg increase, change \>= 30 mmHg decrease; diastolic blood pressure (mmHg), value \<50 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease; pulse rate (beats per minute \[bpm\]) value \<40bpm, value greater than (\>) 120bpm. Clinical significance was determined based on investigator's discretion.
Time frame: From start of study intervention (Day 1) up to end of study, approximately up to 15 months
Number of Participants With Clinically Significant Changes in Vital Signs Abnormalities: MD Cohort
Criteria for abnormal values of vital signs: systolic blood pressure (mmHg) value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; diastolic blood pressure (mmHg), value \<50 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease; pulse rate (bpm) value \< 40bpm, value \> 120bpm. Clinical significance was determined based on investigator's discretion.
Time frame: From start of study intervention (Day 1) up to end of study, approximately of 15.5 months
Number of Participants With Clinically Significant Changes in Laboratory Abnormalities: SAD Cohort
Criteria:Hematology(Activated partial thromboplastin time\>1.1\*upper limit of normal(ULN); Basophils \&eosinophils\>1.2\*ULN; erythrocytes,hematocrit,hemoglobin,lymphocytes,neutrophils \<0.8\*lower limit of normal(LLN); leukocytes \<0.6\*LLN, \>1.5\*ULN; monocytes \>1.2\*ULN; platelets \<0.5\*LLN; prothrombin international randomized ratio \&prothrombin Time \>1.1\*ULN), clinical chemistry (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase \>3.0\*ULN; albumin, protein \<0.8\*LLN, \>1.2\*ULN; bicarbonate, calcium, chloride, potassium \<0.9\*LLN,\>1.1\*ULN; bilirubin \>1.5\*ULN; creatinine \>1.3\*ULN; glucose, Glucose-FASTING \<0.6\*LLN,\>1.5\*ULN; Sodium \<0.95\*LLN,\>1.05\*ULN; Urate: \>1.2\*ULN;Urea Nitrogen: \>1.3\*ULN),urinalysis(Bacteria \> 20;epithelial cells \>=6;granular, hyaline, RBC\&WBC casts \>1;ketones,leukocyte esterase, nitrite, urine glucose, urine hemoglobin, urine protein\>=1,urine erythrocytes,leukocytes \>=20;pH(scalar)\<4.5,\>8.Clinical significance determined on investigator's discretion.
Time frame: From start of study intervention (Day 1) up to end of study, approximately up to 15 months
Number of Participants With Clinically Significant Changes in Laboratory Abnormalities: MD Cohort
Criteria:Hematology(Activated partial thromboplastin time\>1.1\*upper limit of normal(ULN); Basophils \&eosinophils\>1.2\*ULN; erythrocytes,hematocrit,hemoglobin,lymphocytes,neutrophils \<0.8\*lower limit of normal(LLN); leukocytes \<0.6\*LLN, \>1.5\*ULN; monocytes \>1.2\*ULN; platelets \<0.5\*LLN; prothrombin international randomized ratio \&prothrombin Time \>1.1\*ULN), clinical chemistry (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase \>3.0\*ULN; albumin, protein \<0.8\*LLN, \>1.2\*ULN; bicarbonate, calcium, chloride, potassium \<0.9\*LLN,\>1.1\*ULN; bilirubin \>1.5\*ULN; creatinine \>1.3\*ULN; glucose, Glucose-FASTING \<0.6\*LLN,\>1.5\*ULN; Sodium \<0.95\*LLN,\>1.05\*ULN; Urate: \>1.2\*ULN;Urea Nitrogen: \>1.3\*ULN),urinalysis(Bacteria \> 20;epithelial cells \>=6;granular, hyaline, RBC\&WBC casts \>1;ketones,leukocyte esterase, nitrite, urine glucose, urine hemoglobin, urine protein\>=1,urine erythrocytes,leukocytes \>=20;pH(scalar)\<4.5,\>8.Clinical significance determined on investigator's discretion.
Time frame: From start of study intervention (Day 1) up to end of study, approximately of 15.5 months
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Abnormalities: SAD Cohort
Criteria for abnormal values of ECG parameters: pulse rate (PR) interval greater than or equal to (\>=)300 milliseconds (msec); PR interval change \>=25 percent (%) or \>=50 %, QRS interval \>=140 msec and QRS interval change: \>=50%. QT interval using Fridericia's correction (QTcF) range from 450 msec to less than (\<)480 msec, less than (\<) 480 msec to maximum less than or equal to (\<=)500 msec, \>500 msec, \<=30 to \<60 msec and \>=60 msec. Only rows which included at least 1 participant with abnormality are reported in this outcome measure. Clinical significance was determined based on investigator's discretion.
Time frame: From start of study intervention (Day 1) up to end of study, approximately up to 15 months
Number of Participants With Clinically Significant Changes in ECG Abnormalities: MD Cohort
Criteria for abnormal values of ECG parameters: pulse rate (PR) interval greater than or equal to (\>=)300 milliseconds (msec); PR interval change \>=25 percent (%) or \>=50 %, QRS interval \>=140 msec and QRS interval change: \>=50%. QT interval using Fridericia's correction (QTcF) range from 450 msec to less than (\<)480 msec, less than (\<) 480 msec to maximum less than or equal to (\<=)500 msec, \>500 msec, \<=30 to \<60 msec and \>=60 msec. Only rows which included at least 1 participant with abnormality are reported in this outcome measure. Clinical significance was determined based on investigator's discretion.
Time frame: From start of study intervention (Day 1) up to end of study, approximately of 15.5 months
Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Time Point (AUClast) of PF-07261271: SAD Cohort
AUClast was determined using Linear Log trapezoidal method.
Time frame: Predose and 0, 2, 4, 8, 12, 24, 48, 72, 192, 360, 768, 1104, 1464, 2184, 4344, 5064, 5784, 6504, 7224, 7944, 8664, 10824 hours post dose
Area Under the Serum Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-07261271: SAD Cohort
AUCinf was determined as AUClast + (Clast\*/kel), where Clast\* is the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis.
Time frame: Predose and 0, 2, 4, 8, 12, 24, 48, 72, 192, 360, 768, 1104, 1464, 2184, 4344, 5064, 5784, 6504, 7224, 7944, 8664, 10824 hours post dose
Maximum Plasma Concentration (Cmax) of PF-07261271: SAD Cohort
Cmax was defined as maximum serum concentration.
Time frame: Predose and 0, 2, 4, 8, 12, 24, 48, 72, 192, 360, 768, 1104, 1464, 2184, 4344, 5064, 5784, 6504, 7224, 7944, 8664, 10824 hours post dose
Time to Maximum Plasma Concentration (Tmax) of PF-07261271: SAD Cohort
Tmax was defined as time for Cmax.
Time frame: Predose and 0, 2, 4, 8, 12, 24, 48, 72, 192, 360, 768, 1104, 1464, 2184, 4344, 5064, 5784, 6504, 7224, 7944, 8664, 10824 hours post dose
Terminal Elimination Half-life (t1/2) of PF-07261271: SAD Cohort
t1/2 was determined using Loge (2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear -concentration time- curve.
Time frame: Predose and 0, 2, 4, 8, 12, 24, 48, 72, 192, 360, 768, 1104, 1464, 2184, 4344, 5064, 5784, 6504, 7224, 7944, 8664, 10824 hours post dose
Area Under the Concentration Time Profile From Time Zero to Time Tau (τ), the Dosing Interval (AUCtau) of PF-07261271: MD Cohort
AUCtau was defined as area under the concentration time profile from time zero to time tau (τ), the dosing interval, where tau=672 hours for every 4-week dosing. AUCtau was determined by Linear Log trapezoidal method.
Time frame: Predose and 0, 2, 4, 8, 12, 48, 96, 192, 360, 720, 744, 1224, 1584, 1944, 2664, 4104, 4824, 5544, 6264, 6984, 7704, 8424, 9144 and 11304 hours post-dose on Day 1 and 29
Cmax of PF-07261271: MD Cohort
Cmax was defined as maximum serum concentration.
Time frame: Predose and 0, 2, 4, 8, 12, 48, 96, 192, 360, 720, 744, 1224, 1584, 1944, 2664, 4104, 4824, 5544, 6264, 6984, 7704, 8424, 9144 and 11304 hours post-dose on Day 1 and 29
Tmax of PF-07261271: MD Cohort
Tmax was defined as time for Cmax.
Time frame: Predose and 0, 2, 4, 8, 12, 48, 96, 192, 360, 720, 744, 1224, 1584, 1944, 2664, 4104, 4824, 5544, 6264, 6984, 7704, 8424, 9144 and 11304 hours post-dose on Day 1 and 29
Terminal Elimination Half-life (t1/2) of PF-07261271: MD Cohort
t1/2 was determined using Loge (2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear -concentration time- curve.
Time frame: Predose and 0, 2, 4, 8, 12, 48, 96, 192, 360, 720, 744, 1224, 1584, 1944, 2664, 4104, 4824, 5544, 6264, 6984, 7704, 8424, 9144 and 11304 hours post-dose on Day 1 and 29
Number of Participants With Anti-drug Antibodies (ADA) Against PF-07261271: SAD Cohort
ADA positive was defined as ADA titer \>= 100; ADA negative defined as ADA titer \< 100. Baseline was defined as the last pre-dose measurement
Time frame: Baseline up to 15 months
Number of Participants With ADA Against PF-07261271: MD Cohort
ADA positive defined as ADA titer \>= 100; ADA negative defined as ADA titer \< 100. Baseline was defined as the last pre-dose measurement.
Time frame: Baseline up to 15.5 months
Number of Participants With Neutralizing Antibodies (NAb) Against PF-07261271: SAD Cohort
NAb was determined by electrochemiluminescent (ECL) competitive ligand binding assay using the Meso Scale Discovery (MSD) platform.
Time frame: Baseline up to 15 months
Number of Participants With NAb Against PF-07261271: MD Cohort
NAb was determined by electrochemiluminescent (ECL) competitive ligand binding assay using the Meso Scale Discovery (MSD) platform.
Time frame: Baseline up to 15.5 months
A total of 35 participants (27 participants assigned to single ascending dose \[SAD\] cohorts and 8 participants assigned in the multiple doses \[MD\] cohorts) were enrolled in the study.
| Milestone | SAD: Placebo | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: Placebo (Japanese Participants) | SAD: PF-07261271 Dose Level 4 (Japanese Participants) | MD: Placebo | MD: PF-07261271 Dose Level 3 |
|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 2 | 2 | 4 | 6 | 1 | 4 | 2 | 6 |
| Completed | 8 | 2 | 2 | 4 | 6 | 1 | 4 | 2 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the last follow-up date, were considered as TEAEs. AEs included all SAEs and Non-SAEs.
| Participants | SAD: Placebo | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: Placebo (Japanese Participants) | SAD: PF-07261271 Dose Level 4 (Japanese Participants) |
|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs): SAD Cohort | 4 | 1 | 1 | 3 | 2 | 0 | 1 |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the last follow-up date, were considered as TEAEs. AEs included all SAEs and Non-SAEs.
| Participants | MD: Placebo | MD: PF-07261271 Dose Level 3 |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs): MD Cohort | 2 | 5 |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAEs were defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medically significant event.
| Participants | SAD: Placebo | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: Placebo (Japanese Participants) | SAD: PF-07261271 Dose Level 4 (Japanese Participants) |
|---|---|---|---|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs): SAD Cohort | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAEs were defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medically significant event.
| Participants | MD: Placebo | MD: PF-07261271 Dose Level 3 |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs): MD Cohort | 0 | 0 |
Criteria for abnormal values of vital signs: systolic blood pressure (millimeters of mercury \[mmHg\]) value less than (\<) 90 mmHg, change greater than or equal to (\>=) 30 mmHg increase, change \>= 30 mmHg decrease; diastolic blood pressure (mmHg), value \<50 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease; pulse rate (beats per minute \[bpm\]) value \<40bpm, value greater than (\>) 120bpm. Clinical significance was determined based on investigator's discretion.
| Participants | SAD: Placebo | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: Placebo (Japanese Participants) | SAD: PF-07261271 Dose Level 4 (Japanese Participants) |
|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs Abnormalities: SAD Cohort | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Criteria for abnormal values of vital signs: systolic blood pressure (mmHg) value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; diastolic blood pressure (mmHg), value \<50 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease; pulse rate (bpm) value \< 40bpm, value \> 120bpm. Clinical significance was determined based on investigator's discretion.
| Participants | MD: Placebo | MD: PF-07261271 Dose Level 3 |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs Abnormalities: MD Cohort | 0 | 0 |
Criteria:Hematology(Activated partial thromboplastin time\>1.1\*upper limit of normal(ULN); Basophils \&eosinophils\>1.2\*ULN; erythrocytes,hematocrit,hemoglobin,lymphocytes,neutrophils \<0.8\*lower limit of normal(LLN); leukocytes \<0.6\*LLN, \>1.5\*ULN; monocytes \>1.2\*ULN; platelets \<0.5\*LLN; prothrombin international randomized ratio \&prothrombin Time \>1.1\*ULN), clinical chemistry (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase \>3.0\*ULN; albumin, protein \<0.8\*LLN, \>1.2\*ULN; bicarbonate, calcium, chloride, potassium \<0.9\*LLN,\>1.1\*ULN; bilirubin \>1.5\*ULN; creatinine \>1.3\*ULN; glucose, Glucose-FASTING \<0.6\*LLN,\>1.5\*ULN; Sodium \<0.95\*LLN,\>1.05\*ULN; Urate: \>1.2\*ULN;Urea Nitrogen: \>1.3\*ULN),urinalysis(Bacteria \> 20;epithelial cells \>=6;granular, hyaline, RBC\&WBC casts \>1;ketones,leukocyte esterase, nitrite, urine glucose, urine hemoglobin, urine protein\>=1,urine erythrocytes,leukocytes \>=20;pH(scalar)\<4.5,\>8.Clinical significance determined on investigator's discretion.
| Participants | SAD: Placebo | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: Placebo (Japanese Participants) | SAD: PF-07261271 Dose Level 4 (Japanese Participants) |
|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Laboratory Abnormalities: SAD Cohort | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Criteria:Hematology(Activated partial thromboplastin time\>1.1\*upper limit of normal(ULN); Basophils \&eosinophils\>1.2\*ULN; erythrocytes,hematocrit,hemoglobin,lymphocytes,neutrophils \<0.8\*lower limit of normal(LLN); leukocytes \<0.6\*LLN, \>1.5\*ULN; monocytes \>1.2\*ULN; platelets \<0.5\*LLN; prothrombin international randomized ratio \&prothrombin Time \>1.1\*ULN), clinical chemistry (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase \>3.0\*ULN; albumin, protein \<0.8\*LLN, \>1.2\*ULN; bicarbonate, calcium, chloride, potassium \<0.9\*LLN,\>1.1\*ULN; bilirubin \>1.5\*ULN; creatinine \>1.3\*ULN; glucose, Glucose-FASTING \<0.6\*LLN,\>1.5\*ULN; Sodium \<0.95\*LLN,\>1.05\*ULN; Urate: \>1.2\*ULN;Urea Nitrogen: \>1.3\*ULN),urinalysis(Bacteria \> 20;epithelial cells \>=6;granular, hyaline, RBC\&WBC casts \>1;ketones,leukocyte esterase, nitrite, urine glucose, urine hemoglobin, urine protein\>=1,urine erythrocytes,leukocytes \>=20;pH(scalar)\<4.5,\>8.Clinical significance determined on investigator's discretion.
| Participants | MD: Placebo | MD: PF-07261271 Dose Level 3 |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Laboratory Abnormalities: MD Cohort | 0 | 0 |
Criteria for abnormal values of ECG parameters: pulse rate (PR) interval greater than or equal to (\>=)300 milliseconds (msec); PR interval change \>=25 percent (%) or \>=50 %, QRS interval \>=140 msec and QRS interval change: \>=50%. QT interval using Fridericia's correction (QTcF) range from 450 msec to less than (\<)480 msec, less than (\<) 480 msec to maximum less than or equal to (\<=)500 msec, \>500 msec, \<=30 to \<60 msec and \>=60 msec. Only rows which included at least 1 participant with abnormality are reported in this outcome measure. Clinical significance was determined based on investigator's discretion.
| Participants | SAD: Placebo | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: Placebo (Japanese Participants) | SAD: PF-07261271 Dose Level 4 (Japanese Participants) |
|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Abnormalities: SAD Cohort | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Criteria for abnormal values of ECG parameters: pulse rate (PR) interval greater than or equal to (\>=)300 milliseconds (msec); PR interval change \>=25 percent (%) or \>=50 %, QRS interval \>=140 msec and QRS interval change: \>=50%. QT interval using Fridericia's correction (QTcF) range from 450 msec to less than (\<)480 msec, less than (\<) 480 msec to maximum less than or equal to (\<=)500 msec, \>500 msec, \<=30 to \<60 msec and \>=60 msec. Only rows which included at least 1 participant with abnormality are reported in this outcome measure. Clinical significance was determined based on investigator's discretion.
| Participants | MD: Placebo | MD: PF-07261271 Dose Level 3 |
|---|---|---|
| Number of Participants With Clinically Significant Changes in ECG Abnormalities: MD Cohort | 0 | 0 |
AUClast was determined using Linear Log trapezoidal method.
| Nanograms*hour per milliliter | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: PF-07261271 Dose Level 4 (Japanese Participants) |
|---|---|---|---|---|---|
| Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Time Point (AUClast) of PF-07261271: SAD Cohort | NA ± NA | NA ± NA | 65600000 ± 35 | 324100000 ± 18 | 345000000 ± 28 |
AUCinf was determined as AUClast + (Clast\*/kel), where Clast\* is the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis.
| Nanograms*hour per milliliter | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: PF-07261271 Dose Level 4 (Japanese Participants) |
|---|---|---|---|---|---|
| Area Under the Serum Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-07261271: SAD Cohort | NA ± NA | NA ± NA | 61010000 ± 36 | 332600000 ± 18 | 368100000 ± 28 |
Cmax was defined as maximum serum concentration.
| Nanograms per milliliter | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: PF-07261271 Dose Level 4 (Japanese Participants) |
|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of PF-07261271: SAD Cohort | NA ± NA | NA ± NA | 143300 ± 21 | 372800 ± 17 | 313900 ± 31 |
Tmax was defined as time for Cmax.
| Hours | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: PF-07261271 Dose Level 4 (Japanese Participants) |
|---|---|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of PF-07261271: SAD Cohort | NA (NA to NA) | NA (NA to NA) | 2.12 (1.00 to 4.00) | 3.13 (0.967 to 5.53) | 5.26 (2.17 to 48.0) |
t1/2 was determined using Loge (2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear -concentration time- curve.
| Hours | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: PF-07261271 Dose Level 4 (Japanese Participants) |
|---|---|---|---|---|---|
| Terminal Elimination Half-life (t1/2) of PF-07261271: SAD Cohort | NA ± NA | NA ± NA | 330.7 ± 193.29 | 1533 ± 324.39 | 1529 ± 1018.5 |
AUCtau was defined as area under the concentration time profile from time zero to time tau (τ), the dosing interval, where tau=672 hours for every 4-week dosing. AUCtau was determined by Linear Log trapezoidal method.
| Nanograms*hour per milliliter | MD: PF-07261271 Dose Level 3 |
|---|---|
| Day 1 | 17600000 ± 27 |
| Day 29 | 27900000 ± 22 |
Cmax was defined as maximum serum concentration.
| Nanograms*hour per milliliter | MD: PF-07261271 Dose Level 3 |
|---|---|
| Day 1 | 34120 ± 28 |
| Day 29 | 49600 ± 28 |
Tmax was defined as time for Cmax.
| Hours | MD: PF-07261271 Dose Level 3 |
|---|---|
| Day 1 | 253 (48.0 to 338) |
| Day 29 | 170 (48.0 to 172) |
t1/2 was determined using Loge (2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear -concentration time- curve.
| Hours | MD: PF-07261271 Dose Level 3 |
|---|---|
| Terminal Elimination Half-life (t1/2) of PF-07261271: MD Cohort | 1150 ± 856.40 |
ADA positive was defined as ADA titer \>= 100; ADA negative defined as ADA titer \< 100. Baseline was defined as the last pre-dose measurement
| Participants | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: PF-07261271 Dose Level 4 (Japanese Participants) |
|---|---|---|---|---|---|
| Number of Participants With Anti-drug Antibodies (ADA) Against PF-07261271: SAD Cohort | 2 | 2 | 4 (19690.28 to —) | 6 | 4 |
ADA positive defined as ADA titer \>= 100; ADA negative defined as ADA titer \< 100. Baseline was defined as the last pre-dose measurement.
| Participants | MD: PF-07261271 Dose Level 3 |
|---|---|
| Number of Participants With ADA Against PF-07261271: MD Cohort | 6 (32249.01 to —) |
NAb was determined by electrochemiluminescent (ECL) competitive ligand binding assay using the Meso Scale Discovery (MSD) platform.
| Participants | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: PF-07261271 Dose Level 4 (Japanese Participants) |
|---|---|---|---|---|---|
| Number of Participants With Neutralizing Antibodies (NAb) Against PF-07261271: SAD Cohort | 2 | 2 | 4 (19690.28 to —) | 5 | 2 |
NAb was determined by electrochemiluminescent (ECL) competitive ligand binding assay using the Meso Scale Discovery (MSD) platform.
| Participants | MD: PF-07261271 Dose Level 3 |
|---|---|
| Number of Participants With NAb Against PF-07261271: MD Cohort | 5 (32249.01 to —) |
Collected over SAD Cohort: From start of study intervention (Day 1) up to approximately 15 months and MD Cohort: From start of study intervention (Day 1) up to approximately 15.5 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SAD: Placebo | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| SAD: PF-07261271 Dose Level 1 | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| SAD: PF-07261271 Dose Level 2 | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| SAD: PF-07261271 Dose Level 3 | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| SAD: PF-07261271 Dose Level 4 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| SAD: Placebo (Japanese Participants) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| SAD: PF-07261271 Dose Level 4 (Japanese Participants) | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| MD: Placebo | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| MD: PF-07261271 Dose Level 3 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | SAD: Placebo | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: Placebo (Japanese Participants) | SAD: PF-07261271 Dose Level 4 (Japanese Participants) | MD: Placebo | MD: PF-07261271 Dose Level 3 |
|---|---|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 0/8 | 0/2 | 0/2 | 0/4 | 0/6 | 0/1 | 0/4 | 1/2 | 4/6 |
| ArrhythmiaCardiac disorders | 0/8 | 0/2 | 0/2 | 0/4 | 0/6 | 0/1 | 0/4 | 1/2 | 0/6 |
| GastroenteritisInfections and infestations | 0/8 | 0/2 | 0/2 | 0/4 | 0/6 | 0/1 | 0/4 | 1/2 | 0/6 |
| Foot fractureInjury, poisoning and procedural complications | 0/8 | 1/2 | 0/2 | 0/4 | 0/6 | 0/1 | 0/4 | 0/2 | 0/6 |
| Muscle ruptureInjury, poisoning and procedural complications | 0/8 | 1/2 | 0/2 | 0/4 | 0/6 | 0/1 | 0/4 | 0/2 | 0/6 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/8 | 1/2 | 0/2 | 0/4 | 0/6 | 0/1 | 0/4 | 0/2 | 0/6 |
| DizzinessNervous system disorders | 0/8 | 0/2 | 1/2 | 0/4 | 0/6 | 0/1 | 0/4 | 0/2 | 0/6 |
| HeadacheNervous system disorders | 2/8 | 1/2 | 0/2 | 0/4 | 0/6 | 0/1 | 0/4 | 0/2 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 0/8 | 0/2 | 0/2 | 1/4 | 0/6 | 0/1 | 0/4 | 0/2 | 0/6 |
| Fibula fractureInjury, poisoning and procedural complications | 0/8 | 0/2 | 0/2 | 1/4 | 0/6 | 0/1 | 0/4 | 0/2 | 0/6 |
| Age, Customized(Participants) | SAD: Placebo | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: Placebo (Japanese Participants) | SAD: PF-07261271 Dose Level 4 (Japanese Participants) | MD: Placebo | MD: PF-07261271 Dose Level 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Less than (<) 18 Years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18-25 Years | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| 26-35 Years | 2 | 1 | 2 | 2 | 1 | 0 | 0 | 1 | 3 | 12 |
| 36-45 Years | 2 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 6 |
| Greater than (>) 45 Years | 2 | 0 | 0 | 2 | 2 | 1 | 3 | 1 | 3 | 14 |
| Sex: Female, Male(Participants) | SAD: Placebo | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: Placebo (Japanese Participants) | SAD: PF-07261271 Dose Level 4 (Japanese Participants) | MD: Placebo | MD: PF-07261271 Dose Level 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 10 |
| Male | 5 | 1 | 2 | 3 | 5 | 1 | 3 | 1 | 4 | 25 |
| Ethnicity (NIH/OMB)(Participants) | SAD: Placebo | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: Placebo (Japanese Participants) | SAD: PF-07261271 Dose Level 4 (Japanese Participants) | MD: Placebo | MD: PF-07261271 Dose Level 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 6 |
| Not Hispanic or Latino | 6 | 2 | 1 | 4 | 4 | 1 | 4 | 2 | 5 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SAD: Placebo | SAD: PF-07261271 Dose Level 1 | SAD: PF-07261271 Dose Level 2 | SAD: PF-07261271 Dose Level 3 | SAD: PF-07261271 Dose Level 4 | SAD: Placebo (Japanese Participants) | SAD: PF-07261271 Dose Level 4 (Japanese Participants) | MD: Placebo | MD: PF-07261271 Dose Level 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 0 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 5 |
| White | 6 | 2 | 1 | 4 | 3 | 0 | 0 | 1 | 6 | 23 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2022 to primary completion in Feb 2024, 16 months.
Results were first posted in Mar 2025, 1 year after primary completion.
Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 16 months is above that.
Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.